May 13, 2008 - Prana Biotechnology Limited (NASDAQ: PRAN / ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, announced a publication in the Proceedings of the National Academy of Sciences (PNAS) journal, *describing a completely new class of amyloid inhibiting drugs.The reported drugs are directed against the amyloid present in Alzheimer’s Disease, composed of the Abeta protein. By specifically targeting and blocking the metal binding site on the Abeta protein, these drugs change the intrinsic structural properties of Abeta and its oligomers, stopping neuronal toxicity and the subsequent formation of ABeta fibrils... Prana Biotechnology's Press Release -
